Anti-tumor activity of intratumoral xenogeneic urothelial cell monotherapy or in combination with chemotherapy in syngeneic murine models of bladder cancer.
Bladder cancer
immunity
immunotherapy
intratumoral
xenogeneic urothelial cell
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
03
2023
accepted:
13
05
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
Advanced bladder cancer is still an area of high unmet need even with the use of immune checkpoint inhibitors and antibody drug conjugates. Therefore, transformatively novel therapeutic approaches are needed. Xenogeneic cells are capable of inducing potent innate and adaptive immune rejection responses, which properties could turn xenogeneic cells into an immunotherapeutic agent. Here, we investigated the anti-tumor effects of intratumoral xenogeneic urothelial cell (XUC) immunotherapy alone and in combination with chemotherapy in two murine syngeneic models of bladder cancer. In both bladder tumor models, intratumoral XUC treatment suppressed tumor growth, and the efficacy was enhanced with chemotherapy. The experiments on mode of action for intratumoral XUC treatment found that the remarkable local and systemic anti-tumor effects were achieved with significant intratumoral immune cell infiltration and systemic activation of immune cell cytotoxic activity, cytokine IFNγ production and proliferation ability. The intratumoral XUC alone and combined treatment increased T cell natural killer cell infiltration into tumors. In the bilateral tumor model with intratumoral XUC monotherapy or combined therapy, the uninjected tumors at the other side also simultaneously demonstrated significant tumor growth delay. Consequently, intratumoral XUC treatment alone and the combination resulted in elevated chemokine CXCL9/10/11 levels. These data suggest that intratumoral XUC therapy may be useful in the treatment of advanced bladder cancer as a local therapy that injects xenogeneic cells into either primary or distant tumors. By exerting both local and systemic anti-tumor effects, this new treatment would complete the comprehensive cancer management along with systemic approaches.
Types de publication
Journal Article
Langues
eng
Pagination
2285-2306Informations de copyright
AJCR Copyright © 2023.
Déclaration de conflit d'intérêts
None.
Références
World J Urol. 2018 Nov;36(11):1727-1740
pubmed: 29855698
Curr Opin Organ Transplant. 2020 Oct;25(5):449-456
pubmed: 32773503
Curr Opin Organ Transplant. 2017 Dec;22(6):513-521
pubmed: 28901971
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Cancer Treat Rev. 2017 Jan;52:71-81
pubmed: 27951441
Clin Cancer Res. 2021 Feb 1;27(3):665-679
pubmed: 32943460
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Nat Rev Drug Discov. 2013 Jul;12(7):489-92
pubmed: 23812256
Lancet Oncol. 2020 Dec;21(12):1574-1588
pubmed: 32971005
Biotechnol J. 2006 Feb;1(2):138-47
pubmed: 16892244
Cell Transplant. 2021 Jan-Dec;30:9636897211011995
pubmed: 33975464
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Cancer Cell Int. 2018 Jan 16;18:9
pubmed: 29371832
Oncogene. 2008 Oct 6;27(45):5932-43
pubmed: 18836474
Clin Cancer Res. 2003 Apr;9(4):1284-90
pubmed: 12684396
J Transl Med. 2004 Apr 16;2(1):12
pubmed: 15090064
J Clin Oncol. 2019 Apr 20;37(12):992-1000
pubmed: 30785829
Immunol Rev. 2014 Mar;258(1):241-58
pubmed: 24517437
J Natl Compr Canc Netw. 2022 Aug;20(8):866-878
pubmed: 35948037
Int J Surg. 2015 Nov;23(Pt B):211-216
pubmed: 26159291
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
pubmed: 22237781
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Ann Oncol. 2016 Aug;27(8):1492-504
pubmed: 27207108
N Engl J Med. 2021 Mar 25;384(12):1125-1135
pubmed: 33577729
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
J Immunother Cancer. 2013 Nov 18;1:20
pubmed: 24829756
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
Xenotransplantation. 2019 Mar;26(2):e12513
pubmed: 30980428
J Clin Oncol. 2020 Aug 10;38(23):2658-2666
pubmed: 32552471
Lancet Oncol. 2021 Jul;22(7):931-945
pubmed: 34051178
N Engl J Med. 2020 Sep 24;383(13):1218-1230
pubmed: 32945632
Theranostics. 2021 Mar 11;11(11):5365-5386
pubmed: 33859752
Eur J Endocrinol. 2005 Sep;153(3):419-27
pubmed: 16131605
EBioMedicine. 2016 Oct;12:255-262
pubmed: 27592597
J Clin Oncol. 2005 Jul 20;23(21):4602-8
pubmed: 16034041
Cancer Immunol Immunother. 2021 May;70(5):1419-1433
pubmed: 33156394
J Clin Oncol. 2021 Aug 1;39(22):2474-2485
pubmed: 33929895
Semin Cancer Biol. 2002 Feb;12(1):63-71
pubmed: 11926414
Xenotransplantation. 2012 Jan-Feb;19(1):23-30
pubmed: 22360750
Annu Rev Immunol. 2007;25:267-96
pubmed: 17134371
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
J Clin Oncol. 2019 Jul 1;37(19):1608-1616
pubmed: 31100038
Ann Oncol. 2017 Oct 01;28(10):2377-2385
pubmed: 28945858
J Immunol. 2017 Jan 1;198(1):31-39
pubmed: 27994166
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
Nat Rev Immunol. 2018 Sep;18(9):545-558
pubmed: 29921905
Oncoimmunology. 2021 Oct 15;10(1):1984677
pubmed: 34676147
Clin Cancer Res. 2020 Jul 1;26(13):3091-3099
pubmed: 32071116
Cell Transplant. 2019 Mar;28(3):296-305
pubmed: 30675801
JAMA Netw Open. 2020 Jul 1;3(7):e207911
pubmed: 32725245
Nat Rev Cancer. 2016 Feb;16(2):121-6
pubmed: 26822578
Cancer Lett. 2022 Oct 1;545:115478
pubmed: 35902043
Lancet. 1994 Nov 19;344(8934):1402-4
pubmed: 7968077